The addition of trastuzumab to platinum-based regimens was found to be effective and safe in patients with metastatic HER2-positive gastric cancer (ORR: 65%, mPFS: 13 months, and mOS: 24.9 months) [69]. Here, ERBB2 is linked to gastric cancer.